Lenalidomide Capsule
Product Images NDC 76282-696

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 76282-696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01-mar-2015-1 (01 Mar 2015 1)

A Kaplan-Meier curve comparing progression-free survival over months between Lenalidomide and Placebo groups. The curve shows higher survival probability for Lenalidomide than Placebo. Included are hazard ratio with 95% confidence interval, median progression-free survival times, a risk table of subject numbers at intervals, and progression-free survival event counts for each group.*

FDA Label Image

01-mar-2015-2 (01 Mar 2015 2)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over months between lenalidomide and placebo groups. The blue solid line represents lenalidomide, showing higher survival probability than the red dashed line for placebo. The x-axis shows time in months, and the y-axis shows survival probability. A table below details the number of subjects at risk for each group at various time points.*

FDA Label Image

03-mar-2014 (03 Mar 2014)

A Kaplan-Meier survival curve graph comparing overall survival probability over 72 months among three groups labeled Rd Continuous, Rd18, and MPT, with a table below showing the number of subjects at risk at intervals and hazard ratios for the comparisons.*

FDA Label Image

24-may-2013 (24 May 2013)

A Kaplan-Meier survival curve chart depicting Progression Free Survival (months) versus Survival Probability (%) for three treatment groups labeled Rd Continuous, Rd18, and MPT. The chart includes a legend with confidence intervals and a p-value. Below the graph, a table shows the number of subjects at risk over time for each group.*

FDA Label Image

2point5mg (2point5mg)

Label for Lenalidomide 2.5 mg capsules by Exelan Pharmaceuticals Inc. The label states the drug name, dosage strength, quantity of 28 capsules, and a warning for potential birth defects. It includes storage instructions, recommended dosage info, and manufacturer details including Cipla Ltd. and Exelan Pharmaceuticals, Inc. The label features a barcode on the right side.*

FDA Label Image

Mm-study-1 (Mm Study 1)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to disease progression measured in months. The chart compares Lenalidomide/Dex treatment (blue line) against Placebo/Dex (black and red line), with time to progression on the x-axis and proportion of subjects on the y-axis. Statistical details including hazard ratio (HR), confidence interval, and log-rank p-value are displayed.*

FDA Label Image

Mm-study-2 (Mm Study 2)

A Kaplan-Meier survival curve showing the proportion of subjects over time to progression in months. The graph compares two groups: one receiving Lenalidomide/Dex treatment and the other Placebo/Dex, with statistical data including hazard ratio (HR) and p-value noted on the chart.*

FDA Label Image

Augment-trail (Augment Trail)

A Kaplan-Meier survival curve chart showing progression-free survival over 48 months for two groups: Rituximab + Lenalidomide and Rituximab + Placebo. The vertical axis represents survival probability, while the horizontal axis indicates time in months. The chart includes hazard ratio data and a table of the number of subjects at risk at various time points.*

FDA Label Image

Image Description (Lenali 1)

Chemical structure diagram of Lenalidomide, a small molecule with a fused bicyclic ring system including an amino group and lactam functionalities, consistent with its known molecular structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.